Reverse the Resistance to PARP Inhibitors

被引:67
|
作者
Kim, Yevgeniy [1 ]
Kim, Aleksei [1 ]
Sharip, Ainur [1 ]
Sharip, Aigul [1 ]
Jiang, Juhong [2 ]
Yang, Qing [1 ]
Xie, Yingqiu [1 ]
机构
[1] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, 53 Kabanbay Batyr Ave, Astana 010000, Kazakhstan
[2] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2017年 / 13卷 / 02期
基金
中国国家自然科学基金;
关键词
PARP; PARP inhibitor; drug resistance; DNA repair; STRAND-BREAK REPAIR; SHOCK-PROTEIN; 90; HOMOLOGOUS RECOMBINATION; DNA-REPAIR; SECONDARY MUTATIONS; SYNTHETIC LETHALITY; MILD HYPERTHERMIA; TUMOR SUPPRESSION; CANCER-CELLS; BRCA1;
D O I
10.7150/ijbs.17240
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the DNA repair machineries is activated by Poly ( ADP- ribose) Polymerase ( PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single- strand DNA, thus decreasing the chances of generating double- strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor ( PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 50 条
  • [31] Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
    Janysek, Dawn C.
    Kim, Jennifer
    Duijf, Pascal H. G.
    Dray, Eloise
    TRANSLATIONAL ONCOLOGY, 2021, 14 (03):
  • [32] PARP Inhibitors in Prostate Cancer
    Grewal, Kabir
    Grewal, Kayanaat
    Tabbara, Imad A.
    ANTICANCER RESEARCH, 2021, 41 (02) : 551 - 556
  • [33] PARP molecular functions and applications of PARP inhibitors in cancer treatment
    Yuhan Guo
    Boyang Fan
    Mo Li
    Genome Instability & Disease, 2023, 4 (3) : 137 - 153
  • [34] PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
    Jiang, Xuan
    Li, Xiaoying
    Li, Weihua
    Bai, Huimin
    Zhang, Zhenyu
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (04) : 2303 - 2313
  • [35] Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
    Kim, Dae-Seok
    Camacho, Cristel V.
    Kraus, W. Lee
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2021, 53 (01) : 42 - 51
  • [36] Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
    Le, Bac Viet
    Podszywalow-Bartnicka, Paulina
    Piwocka, Katarzyna
    Skorski, Tomasz
    CANCERS, 2022, 14 (23)
  • [37] PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
    Fritz, Claire
    Portwood, Scott M.
    Przespolewski, Amanda
    Wang, Eunice S.
    BLOOD REVIEWS, 2021, 45
  • [38] Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
    Zheng, Feiyue
    Zhang, Yi
    Chen, Shuang
    Weng, Xiang
    Rao, Yuefeng
    Fang, Hongmei
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [39] Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
    Soung, Young-Hwa
    Chung, Jun
    BIOMOLECULES, 2023, 13 (10)
  • [40] Advances in PARP Inhibitors for Prostate Cancer
    Tisseverasinghe, Steven
    Bahoric, Boris
    Anidjar, Maurice
    Probst, Stephan
    Niazi, Tamim
    CANCERS, 2023, 15 (06)